Health
PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer – Targeted Oncology
With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant…
The December 2020 approval of the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)positive lesions in patients with prostate cancer, Gallium 68 PSMA-11 (Ga 68 PSMA-11), heralded an exciting new chapter in the diagnosis and treatment of metastatic castration-resistant prostate cancer (mCRPC). With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly…
-
Noosa News11 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General23 hours agoAn open letter to pro-Palestinian protesters
-
Business13 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
General9 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse